Stockscreener 앱 받기
2.71
16.31%
0.38
시간 외 거래:
2.63
-0.08
-2.95%
전일 마감가:
$2.33
열려 있는:
$2.27
하루 거래량:
46,439
Relative Volume:
0.93
시가총액:
$6.08M
수익:
-
순이익/손실:
$-20.85M
주가수익비율:
-0.1679
EPS:
-16.1435
순현금흐름:
$-15.72M
1주 성능:
+72.61%
1개월 성능:
+53.11%
6개월 성능:
-30.15%
1년 성능:
+437.38%
1일 변동 폭
$2.2201
$2.73
1주일 범위
$1.51
$2.73
52주 변동 폭
$0.2701
$13.40
Indaptus Therapeutics Inc Stock (INDP) Company Profile
명칭
Indaptus Therapeutics Inc
전화
(646) 427-2727
주소
3 COLUMBUS CIRCLE, NEW YORK
Compare INDP vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INDP
Indaptus Therapeutics Inc
|
2.71 | 5.22M | 0 | -20.85M | -15.72M | -16.14 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Indaptus Therapeutics Inc 주식(INDP)의 최신 뉴스
Momentum Shift: Should I hold or sell Indaptus Therapeutics Inc nowInflation Watch & Daily Stock Trend Watchlist - baoquankhu1.vn
Published on: 2026-04-13 10:12:55 - baoquankhu1.vn
[SCHEDULE 13G/A] Indaptus Therapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan
Risk Off: Why is Indaptus Therapeutics Inc stock going up2026 Volume Leaders & High Yield Equity Trading Tips - baoquankhu1.vn
Indaptus Therapeutics, Inc. (INDP) stock news today: Live updates - Bitget
Indaptus Therapeutics Appoints Yu Ding as New Chief Financial Officer Effective April 2026 - Minichart
Indaptus Therapeutics Names New CFO, Refreshes Board Oversight - The Globe and Mail
Indaptus Therapeutics announces CFO transition and new board appointment - Investing.com
INDP Technical Analysis & Stock Price Forecast - Intellectia AI
Indaptus Therapeutics announces CFO transition and new board appointment By Investing.com - Investing.com South Africa
Indaptus appoints Yu Ding as CFO; Nir Sassi resigns - TradingView — Track All Markets
Indaptus Therapeutics (INDP) names new CFO and independent director - Stock Titan
Indaptus Therapeutics Inc. (INDP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Yun Yao converts preferred into 41.99M Indaptus (INDP) shares - Stock Titan
SINO LION VENTURES (INDP) discloses 38.9M-share Indaptus stake via preferred conversion - Stock Titan
Indaptus (INDP) CEO converts preferred stock into 11.25M common shares - Stock Titan
Volatility Watch: Is Indaptus Therapeutics Inc stock undervalued right now2026 Catalysts & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Risk Hedge: Whats next for Indaptus Therapeutics Inc stock2026 Action & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Revenue Check: Why is Indaptus Therapeutics Inc stock going upTrade Risk Assessment & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
New investor group takes large control stake in Indaptus Therapeutics (INDP) - Stock Titan
Yun Yao Leads Investor Group, Secures CEO Change at Indaptus Therapeutics, Inc. with 37.8% Stake - TradingView
Market Pulse: Why is Indaptus Therapeutics Inc stock going downWeekly Risk Summary & Safe Entry Zone Tips - baoquankhu1.vn
Rate Cut: Should I hold or sell Indaptus Therapeutics Inc nowTrade Analysis Report & AI Powered Market Entry Ideas - baoquankhu1.vn
Indaptus Therapeutics : 10-K 2025 Annual Report - marketscreener.com
Insider Buyers Lose US$40k As Indaptus Therapeutics Sheds US$583k - simplywall.st
Indaptus Therapeutics, Inc. Files Form 8-K Reporting Changes in Control – Key SEC Filing Details 3 - Minichart
Indaptus Therapeutics (INDP) shifts control and names Junyi Dai CEO-Chair - Stock Titan
Indaptus Therapeutics, Inc. Announces CEO Changes - MarketScreener
Lazar cuts Indaptus (NASDAQ: INDP) preferred stake, resigns as co‑CEO but stays on board - Stock Titan
Indaptus (INDP) director exits Series AAA stake, trims Series AA - Stock Titan
Short Covering: Does Indaptus Therapeutics Inc have declining or rising EPS2026 Major Catalysts & Safe Entry Zone Identification - baoquankhu1.vn
Market Outlook: Does Indaptus Therapeutics Inc have declining or rising EPSPortfolio Performance Report & Trade Opportunity Analysis Reports - baoquankhu1.vn
Indaptus Therapeutics, Inc. 2025 Annual Report: Company Overview, Risks, Investment Transaction, and Regulatory Compliance - Minichart
Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Lazar-backed Indaptus Therapeutics (NASDAQ: INDP) halts trials, eyes strategic deal - Stock Titan
CEO Change: Will PANL stock hit new highs in YEAR2026 Sector Moves & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Published on: 2026-03-17 18:45:40 - baoquankhu1.vn
Indaptus Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - MarketScreener
INDPIndaptus Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Indaptus Therapeutics (INDP) Stock Analysis Report | Financials & Insights - Benzinga Japan
Why Indaptus Therapeutics Inc. stock remains on buy listsWeekly Stock Report & Safe Entry Momentum Tips - Naître et grandir
Will Indaptus Therapeutics Inc. stock keep outperforming rivalsWeekly Trade Summary & Safe Entry Zone Identification - Naître et grandir
Indaptus Therapeutics Inc expected to post a loss of $4.36 a shareEarnings Preview - TradingView
Does Indaptus Therapeutics Inc. have declining or rising EPSPortfolio Profit Report & Daily Stock Momentum Reports - Mfd.ru
Why Did INDP Stock Gain 12% Today? - Stocktwits
Indaptus Therapeutics (INDP) Expected to Announce Quarterly Earnings on Thursday - Defense World
CapEx per share of Indaptus Therapeutics, Inc. – NASDAQ:INDP - TradingView
Lazar takes 98% control stake in Indaptus Therapeutics (INDP) via $6M deal - Stock Titan
Indaptus Therapeutics, Inc. Announces $3.0 Million Registered Direct Offering and Concurrent Private Placement - marketscreener.com
Indaptus Shareholders Approve Major Charter and Capital Changes - The Globe and Mail
Indaptus Therapeutics shareholders approve preferred stock conversion and company charter amendments - Investing.com
Indaptus Therapeutics Inc (INDP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):